Eyepoint’s Phase 3 LUGANO results for Duravyu fell short of its primary goal against Eylea aflibercept in wet age-related macular degeneration, pushing the company to reassess its regulatory path. Separate reporting highlighted that market reaction was sharp, with investor attention shifting to rival entrants in less-frequent injection regimens. In parallel, Argenx reported that Vyvgart Hytrulo (subcutaneous efgartigimod alfa) met a Phase 3 endpoint in immune-mediated necrotizing myopathy, a myositis subtype with no approved targeted options. The top-line readout showed statistical significance in an overall analysis focused on Total Improvement Score, with steroid tapering and safety described as consistent with prior experience. Taken together, the updates underscore how quickly late-stage ophthalmology and autoimmune programs can reprice based on primary endpoints, especially when the competitive field is built around dosing convenience and subgroup differentiation.